Overview of Dr. Saltos
Dr. Andreas Saltos is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of Maryland School of Medicine and has been in practice 8 years. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 20 publications and over 500 citings.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Education & Training
- University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2015 - 2018
- University of MarylandResidency, Internal Medicine, 2012 - 2015
- University of Maryland School of MedicineClass of 2012
Certifications & Licensure
- FL State Medical License 2015 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors Start of enrollment: 2016 Nov 23
- Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer Start of enrollment: 2018 Nov 29
- Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Start of enrollment: 2019 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 71 citationsUpdate on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC).Andreas Saltos, Michael Shafique, Alberto Chiappori
Frontiers in Oncology. 2020-07-16 - 353 citationsTrastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa
The New England Journal of Medicine. 2021-09-18 - 183 citationsTumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.Benjamin C. Creelan, Chao Wang, Jamie K. Teer, Eric M. Toloza, Jiqiang Yao
Nature Medicine. 2021-08-12
Press Mentions
- Moffitt Initiates Groundbreaking Clinical Trial with Oncolytic Virus for Non-Small Cell Lung CancerMay 1st, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: